Objective-To confirm the apparent effectiveness of botulinum toxin (BTX) in hemiparetic patients with ankle plantar flexor and foot invertor spasticity. Methods-Twenty three hemiparetic patients with spasticity of the ankle plantar flexors and foot invertors were included in a randomised double blind, placebo controlled study with BTX. Patients were examined on days 0, 30, 90, and 120 and received one injection of BTX and one of placebo in a random order at day 0 and day 90. Results-Patients reported a clear subjective improvement in foot spasticity after BTX (P = 0-0014) but not after placebo. Significant changes were noted in Ashworth scale values for ankle extensors (P < 0.0001) and invertors (P = 0.0002), and for active ankle dorsiflexion (P = 0-0001). Gait velocity was slightly but not significantly (P = 0-0731) improved after BTX injections. The severity of spasticity did not modify treatment efficacy, but BTX was less effective in patients with longer duration of spasticity (P = 0-0081). Conclusion-The efficacy of BTX injections in the treatment of spastic foot suggests that BTX may be particularly useful during the first year after a stroke.
Spasticity of the ankle plantar flexor and foot invertors is a major problem in the management of hemiparetic patients and may seriously impair walking rehabilitation. None of the usual treatments is totally satisfying in this focal form of spasticity. Oral 4 Meanwhile, pronounced improvement of spasticity with few side effects has been reported after selective neurotomy. 6 Botulinum toxin (BTX) may represent a useful alternative approach. For roughly 10 years, it has been successfully used in the treatment of focal dystonia and various neurological disorders.78 This has recently led to the suggestion that it might help in the treatment of spasticity.9 '°Its temporary effect makes BTX particularly interesting in treating patients who are likely to recover ambulation in the first few months after a stroke. Previous open trial studies have reported substantial amelioration in the muscle tone of spastic patients, both in the upper9 11-13 and lower limbs.'0 [13] [14] [15] [16] [17] [18] [19] To confirm the apparent effectiveness of BTX, double blind, placebo controlled studies have been called for, 20 21 and this we set out to do in a population of adult hemiparetic patients with ankle plantar flexor and foot invertor spasticity.
Methods
All patients in this study were referred for management of spasticity of the foot and came from several rehabilitation centres in southwest France. They gave their informed consent to participate in this double blind study. Inclusion criteria were the presence, for at least three months, of moderate to severe spasticity of the ankle plantar flexors and foot invertors and a lack of response to conventional physical and medical treatment. No change in antispastic treatment was allowed during the course of the study. Exclusion criteria included fixed joint posture, pregnancy, and neuromuscular diseases. All patients continued with active physiotherapy after the injections.
The patients were examined at day 0, 30, 90, and 120 and received one injection of botulinum toxin and one of placebo in a random order, one at day 0 and the other at day 90. Treatment efficacy was reported subjectively by patients (on a scale of 0 to 3) and objectively by clinical rating scales. The modified Ashworth scale22 and the Fugl-Meyer scale23 for the inferior limb were applied by an experienced physiotherapist (JLD) and data were recorded by a neurologist (PB). In this manner, the first did not know the scores he had given the same patient previously. The second performed the injection but did not clinically evaluate the patients. For evaluation of active dorsiflexion, a global score (from 0 to 6) was calculated from the three items of the FuglMeyer scale which directly concern active ankle dorsiflexion in the supine, sitting, and A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients Among the 20 others, the subjective score increased by at least two points in 13. Four patients reported an improvement of one point after placebo. There was a clear difference (P = 0-0014) in patients' subjective scores between BTX (1 5 (SD 0 8)) and placebo (0-2 (SD 04)). Figure 1 shows the responses of patients who received BTX (n = 10) or placebo (n = 13) as the first injection. When placebo was given at day 0, a slight but nonsignificant evolution in gait velocity and Ashworth ankle scores was noted between day 0 and day 90 sessions. Except for gait velocity, all clinical scores were statistically different between day 90 and day 120 (P < 0-01). When BTX was given at day 0, a difference was found between day 0 and day 90 (but not with day 120) for the video (P = 0-0103) and the Fugl-Meyer score (P = 0 0067). Although an increase in gait velocity was noticed at day 30 the difference was not statistically significant due to the large SD. Most importantly, a difference was found between day 0 and day 30 for the three clinical ankle scores: Ashworth extensors, Ashworth invertors, and active dorsiflexion (P < 0-0001). The difference was still significant between day 0 and day 90 or day 120 for both extensor (P = 0-0067, P = 0 0058) and invertor (P = 0-0087, P = 0-01 14) Ashworth scores but not between day 0 and day 90 (P = 0 2964) or day 120 (P = 0-2616) for active dorsiflexion. Table 2 shows pooled clinical data from the 23 patients before and one month after BTX injections. The video score was significantly higher (P = 0 0002) after BTX injection but not after placebo. Gait velocity improved (velocity change > 7 cm/s) in only eight of 22 patients after BTX injection. Results from one patient were not used in data analysis as she was not able to walk independently at inclusion. The difference in gait velocity before and after BTX injection did not quite reach significance (P = 0-0731). A slight but significant improvement in the Fugl-Meyer score (P = 0-0028) was found after BTX injection. Also, after treatment with BTX, two patients who previously could not walk independently were able to walk alone with an ordinary stick, two were able to exchange their tripod stick for an ordinary stick, and two others no longer needed sticks. The Ashworth scale values for (fig 2) showed that the greatest improvement occurred when active dorsiflexion was performed in the supine (1 1 of 22 patients, (P = 0 0027) and sitting positions (10 of 22 patients, P = 0-0013) during volitional synergistic movements of lower limb muscles. An improvement in active dorsiflexion was found in only five of 22 patients in the upright position (P = 0-0143). In the supine position, no modification in active ankle extension was noted before and after BTX injection (P = 06986). The Ashworth score for ankle extensors was neither influenced by age and sex, nor the side of hemiplegia and type of stroke. The severity of spasticity at inclusion, evaluated using the Ashworth score for ankle extensors and invertors, had no influence on the efficacy of BTX injections (table 3) . Patients with recent spasticity (duration < 52 weeks, n = 15) improved more than those presenting longer term spasticity (duration > 52 weeks, n = 8) after BTX injection for both the ankle extensor Ashworth score (P = 0-0081) and patients' subjective scores (P = 00014). No general or local side effects were reported by patients except for local pain at the site of injection (n = 3).
Discussion
Our data clearly show that BTX injections decreased foot spasticity in hemiparetic patients whereas placebo had little effect. A spontaneous recovery between two sessions would be an unlikely explanation of the improvement after BTX injections. Indeed, evolution in clinical rating scales between day 0 and day 90 was not significant in the group of patients who received placebo first, and no differences in clinical characteristics were found between the two groups of patients. The placebo injection at day 90 in the group of patients who received BTX at day 0 had little effect but in this cross over study, we cannot exclude the possibility of these patients having already improved to their possible maximum. Although physiotherapy had a clear effect on correction of posture during ambulation, it was not clearly effective on foot spasticity.
Most of the differences between BTX and placebo were significant in the diverse clinical scales employed, for both passive and active movements. The more obvious improvement during passive testing compared with that of active movements is probably due to antagonist muscle paresis. Indeed, active ankle dorsiflexion will be facilitated by BTX injection of the plantarflexors if the ankle dorsiflexor muscles (tibialis anterior) are not overly paretic. On the other hand, a decrease in foot spasticity may modify the balance of segmental tonic influences and improve volitional control of antagonist muscles. It may also facilitate motor command by compensatory central programmes which are likely to play a part in walking rehabilitation. This is why it seems necessary to propose a comprehensive rehabilitation programme along with BTX injections. 25 Although gait stance was reported by patients as improved, the effect of BTX injections on walking velocity did not reach significance. Many factors may interfere with walking velocity in hemiparetic patients, explaining the variability. Indeed, some patients who initially walked with the help of some devices (stick, semirigid ankle orthesis) no longer needed them after BTX treatment. They may, however, walk more slowly through caution or apprehension. The lack of improvement in gait velocity could also reflect a detrimental effect of the toxin, which might produce too much weakness in plantar flexion. Against this hypothesis is the fact that, at the doses used in the present study, we found neither differences before and after BTX injections in the active ankle extension score of the Fugl-Meyer scale nor in clinical testing of foot extension strength. The mechanism by which BTX may improve foot spasticity during walking was not investigated in the present study, based on clinical evaluation. Previous authors using three dimensional gait analysis have reported that foot placement and stability, stride length, and foot force point of action were improved by BTX injections in hemiparetic patients. '8 19 This double blind crossover study was designed to compare the benefits from BTX or placebo treatment in each patient, not to provide an accurate evaluation of the duration of treatment efficacy. Duration 
